Goldman Sachs Adds 4 Companies to US Conviction List With Huge Double-Digit Upside Potential

The common factor across the additions is not “quality” so much as self-help with visible operating leverage. That matters because the market is still paying up for secular growth while discounting names where margin inflection is more execution-driven than narrative-driven; this creates a relative-value pocket in businesses with pricing power, recurring revenue, or contract-like economics. The cleaner expression is that the list is tilting toward cash-flow conversion stories where consensus is still underestimating the slope of the margin recovery.

TPG is the most interesting second-order beneficiary. If public market volatility keeps suppressing fundraising for weaker peers, capital is likely to concentrate further in scaled platforms with diversified fee streams, which should widen the gap between incumbents and sub-scale alternatives. The key risk is that management fee growth can look excellent on paper yet fail to translate into durable FRE expansion if incentive fees and realizations remain muted for another few quarters.

CWST and TSN are both more cyclical than the headlines suggest, but in opposite ways: CWST has a quasi-inflation-linked earnings profile that should hold up if pricing discipline remains intact, while TSN is effectively a beneficiary of normalization in protein spreads and better execution. The contrarian concern on TSN is that the market may be extrapolating a clean margin path too aggressively; protein businesses often look best right before input volatility or customer pushback compresses the next leg of gains. For Block, the risk/reward is still tied to adoption efficiency: if product initiatives do not improve active user monetization by mid-year, the market can quickly re-rate the story back to “optional exposure” rather than durable platform compounding.